Given their complementary mechanisms of action, insulin and GLP-1 RAs have been combined into fixed-ratio formulations to simplify treatment and enhance glycemic control while minimizing weight gain and the risk of hypoglycemia. The gene discussed is INS; the disease is Hypoglycemia.